271 related articles for article (PubMed ID: 21915801)
1. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.
Ge Y; Domschke C; Stoiber N; Schott S; Heil J; Rom J; Blumenstein M; Thum J; Sohn C; Schneeweiss A; Beckhove P; Schuetz F
Cancer Immunol Immunother; 2012 Mar; 61(3):353-62. PubMed ID: 21915801
[TBL] [Abstract][Full Text] [Related]
2. Combined oral low-dose cyclophosphamide endocrine therapy may improve clinical response among patients with metastatic breast cancer via Tregs in TLSs.
Zhao Y; Wang S; Lv S; Liu X; Li W; Song Y; Rong D; Zheng P; Huang H; Zheng H
Sci Rep; 2024 Jun; 14(1):13432. PubMed ID: 38862586
[TBL] [Abstract][Full Text] [Related]
3. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Kwa M; Li X; Novik Y; Oratz R; Jhaveri K; Wu J; Gu P; Meyers M; Muggia F; Speyer J; Iwano A; Bonakdar M; Kozhaya L; Tavukcuoglu E; Budan B; Raad R; Goldberg JD; Unutmaz D; Adams S
Breast Cancer Res Treat; 2018 Feb; 168(1):57-67. PubMed ID: 29124456
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
Mitchell L; Thamm DH; Biller BJ
J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
[TBL] [Abstract][Full Text] [Related]
5. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
[TBL] [Abstract][Full Text] [Related]
6. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
9. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Banissi C; Ghiringhelli F; Chen L; Carpentier AF
Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
[TBL] [Abstract][Full Text] [Related]
10. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes.
Audia S; Nicolas A; Cathelin D; Larmonier N; Ferrand C; Foucher P; Fanton A; Bergoin E; Maynadie M; Arnould L; Bateman A; Lorcerie B; Solary E; Chauffert B; Bonnotte B
Clin Exp Immunol; 2007 Dec; 150(3):523-30. PubMed ID: 17956583
[TBL] [Abstract][Full Text] [Related]
11. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
Ghiringhelli F; Menard C; Puig PE; Ladoire S; Roux S; Martin F; Solary E; Le Cesne A; Zitvogel L; Chauffert B
Cancer Immunol Immunother; 2007 May; 56(5):641-8. PubMed ID: 16960692
[TBL] [Abstract][Full Text] [Related]
12. All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.
Van YH; Lee WH; Ortiz S; Lee MH; Qin HJ; Liu CP
Diabetes; 2009 Jan; 58(1):146-55. PubMed ID: 18984738
[TBL] [Abstract][Full Text] [Related]
13. Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.
Voo KS; Bover L; Harline ML; Weng J; Sugimoto N; Liu YJ
J Immunol; 2014 Jul; 193(2):627-34. PubMed ID: 24928999
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
15. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway.
Zhong H; Lai Y; Zhang R; Daoud A; Feng Q; Zhou J; Shang J
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023984
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
Huijts CM; Santegoets SJ; van den Eertwegh AJ; Pijpers LS; Haanen JB; de Gruijl TD; Verheul HM; van der Vliet HJ
BMC Cancer; 2011 Nov; 11():505. PubMed ID: 22129044
[TBL] [Abstract][Full Text] [Related]
17. YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage.
Zheng J; Liu P; Yang X
Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):1006-14. PubMed ID: 23169344
[TBL] [Abstract][Full Text] [Related]
18. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
Camisaschi C; Filipazzi P; Tazzari M; Casati C; Beretta V; Pilla L; Patuzzo R; Maurichi A; Cova A; Maio M; Chiarion-Sileni V; Tragni G; Santinami M; Vergani B; Villa A; Berti E; Umansky L; Beckhove P; Umansky V; Parmiani G; Rivoltini L; Castelli C
Cancer Immunol Immunother; 2013 May; 62(5):897-908. PubMed ID: 23589107
[TBL] [Abstract][Full Text] [Related]
19. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor.
Condomines M; Quittet P; Lu ZY; Nadal L; Latry P; Lopez E; Baudard M; Requirand G; Duperray C; Schved JF; Rossi JF; Tarte K; Klein B
J Immunol; 2006 Jun; 176(11):6631-9. PubMed ID: 16709821
[TBL] [Abstract][Full Text] [Related]
20. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
